Paris, France

Sylvie Gontier


 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Sylvie Gontier: Innovator in Anti-Cancer Compounds

Introduction

Sylvie Gontier is a prominent inventor based in Paris, France. She has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-cancer compounds. With a total of 2 patents, her work is paving the way for innovative treatments in oncology.

Latest Patents

Gontier's latest patents focus on an anti-cancer compound and pharmaceutical composition. The invention relates to a compound of formula (I), specifically in the levorotatory form (1a). This form has a rotatory power [α]D=−38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound can exist as a base or an acid addition salt, particularly a pharmaceutically acceptable acid. It serves as a selective Aurora A and B kinase inhibitor, making it a potential candidate for anticancer drug development.

Career Highlights

Sylvie Gontier is currently employed at Sanofi, a leading global healthcare company. Her work at Sanofi has allowed her to focus on innovative pharmaceutical solutions that address critical health challenges. Gontier's expertise in the field has positioned her as a key player in the development of new therapeutic agents.

Collaborations

Throughout her career, Gontier has collaborated with notable colleagues, including Jean-Christophe Carry and Michel Cheve. These collaborations have enhanced her research and contributed to the advancement of her projects.

Conclusion

Sylvie Gontier's contributions to the field of anti-cancer compounds highlight her innovative spirit and dedication to improving healthcare. Her work continues to inspire advancements in pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…